Results 111 to 120 of about 2,457 (145)

Macrolide-resistant <i>Bordetella pertussis</i> strain identified during an ongoing epidemic, Finland, January to October 2024. [PDF]

open access: yesEuro Surveill
Miettinen M   +7 more
europepmc   +1 more source

Antibody waning and Bordetella pertussis resurgence after the COVID-19 pandemic in the Netherlands. [PDF]

open access: yesNat Commun
Gaasbeek CM   +10 more
europepmc   +1 more source

Type 5 secretion system antigens as vaccines against Gram-negative bacterial infections. [PDF]

open access: yesNPJ Vaccines
Da Costa RM   +4 more
europepmc   +1 more source

Mechanisms of natural and vaccine-induced immunity to Bordetella pertussis. [PDF]

open access: yesPLoS Pathog
Borkner L   +4 more
europepmc   +1 more source

SeaB is a conserved <i>Salmonella enterica</i> extracellular matrix binding protein involved in biofilm formation and infection. [PDF]

open access: yesInfect Immun
Da Costa RM   +9 more
europepmc   +1 more source

Resurgence of Bordetella pertussis, including one macrolide-resistant isolate, France, 2024. [PDF]

open access: yesEuro Surveill
Rodrigues C   +12 more
europepmc   +1 more source

A BcfA-containing intranasal vaccine generated T<sub>H</sub>17 immunity and reduced B. bronchiseptica colonization and disease in mice. [PDF]

open access: yesNPJ Vaccines
Aubrey AR   +9 more
europepmc   +1 more source

Pertussis Outbreak During 2023 in Gipuzkoa, North Spain. [PDF]

open access: yesVaccines (Basel)
Marimón JM   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy